| Ethyl 2,4-dibromobutyrate |
2,4-二溴丁酸乙酯 |
36847-51-5 |
| Osimertinib Impurity C |
奥西替尼杂质2 |
2227103-37-7 |
| SNDX-5613 |
SNDX-5613 |
2169919-21-3 |
| VTP50469 |
VTP50469 |
2169916-18-9 |
| JNJ-63576253(TRC-253) |
化合物JNJ63576253 |
2110428-64-1 |
| Ketohexokinase inhibitor 1 |
PF-06835919 |
2102501-84-6 |
| SMS2-IN-1 |
SMS2-IN-1 |
2098890-15-2 |
| LOXO-195 |
LOXO-195 |
2097002-61-2 |
| Nintedanib Impurity L |
Nintedanib Impurity L |
2095596-44-2 |
| Heptadecan-9-yl 8-((2-hydroxyethyl)(8-nonyloxy)-8-oxooctyl)amino)octanoate |
Heptadecan-9-yl 8-((2-hydroxyethyl)(8-nonyloxy)-8-oxooctyl)amino)octanoate |
2089251-33-0 |
| TC13172 |
TCI3172 |
2093393-05-4 |
| ALC-0315 |
ALC-0315 |
2036272-55-4 |
| Nonadecanedioic acid, 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]-, 1,19-bis(2-butyloctyl) ester |
A9 |
2036272-50-9 |
| Gefitinib-based PROTAC 3 |
Gefitinib-based PROTAC 3 |
2230821-27-7 |
| GSK2807 Trifluoroacetate |
GSK2807 Trifluoroacetate |
2245255-66-5 |
| (7-BROMO-2,3-DIHYDROBENZO[B][1,4]DIOXIN-2-YL)METHANOL |
(7-溴-2,3-二氢苯并[B][1,4]二氧杂环己烯-2-基)甲醇 |
280752-79-6 |
| tert-Butyl 3-amino-2,2-dimethylpropanoate |
3-氨基-2,2-二甲基丙酸叔丁酯 |
259794-53-1 |
| PF-04965842(Abrocitinib) |
PF-04965842(阿布罗替尼) |
1622902-68-4 |
| methyl 3-bromo-1-methyl-1H-indole-5-carboxylate |
3-溴-1-甲基-1H-吲哚-5-羧酸甲酯 |
1609967-66-9 |
| 1H-Imidazole, 5-cyclopropyl-1-methyl- |
1-甲基-5-环丙基咪唑 |
1595731-50-2 |
QQ
